Evolent Health, Inc. (NYSE:EVH) Shares Purchased by Altshuler Shaham Ltd

Altshuler Shaham Ltd raised its holdings in Evolent Health, Inc. (NYSE:EVH) by 170.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,609 shares of the technology company’s stock after acquiring an additional 25,609 shares during the quarter. Altshuler Shaham Ltd’s holdings in Evolent Health were worth $1,341,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its holdings in Evolent Health by 8.7% during the third quarter. Bank of New York Mellon Corp now owns 1,655,609 shares of the technology company’s stock worth $45,082,000 after buying an additional 133,038 shares in the last quarter. Brown Advisory Inc. raised its holdings in Evolent Health by 17.8% in the third quarter. Brown Advisory Inc. now owns 36,870 shares of the technology company’s stock valued at $1,004,000 after buying an additional 5,564 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Evolent Health by 20.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,678 shares of the technology company’s stock worth $563,000 after buying an additional 3,514 shares during the period. Summit Creek Advisors LLC increased its position in shares of Evolent Health by 0.4% in the third quarter. Summit Creek Advisors LLC now owns 559,495 shares of the technology company’s stock worth $15,235,000 after acquiring an additional 2,425 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Evolent Health by 9.0% during the 3rd quarter. Teacher Retirement System of Texas now owns 8,293 shares of the technology company’s stock valued at $226,000 after acquiring an additional 685 shares in the last quarter.

Wall Street Analysts Forecast Growth

EVH has been the subject of several recent research reports. JMP Securities increased their price objective on shares of Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a research report on Friday, February 23rd. Canaccord Genuity Group reduced their target price on Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, March 28th. Oppenheimer started coverage on shares of Evolent Health in a research report on Friday, March 1st. They issued an “outperform” rating and a $45.00 target price for the company. JPMorgan Chase & Co. reduced their price target on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a research report on Friday, March 15th. Finally, Citigroup started coverage on Evolent Health in a research note on Monday, April 22nd. They set a “buy” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Evolent Health has an average rating of “Moderate Buy” and an average price target of $42.70.

Evolent Health Price Performance

Shares of EVH traded down $0.30 during midday trading on Thursday, reaching $26.97. The stock had a trading volume of 1,637,168 shares, compared to its average volume of 951,209. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01. Evolent Health, Inc. has a 52 week low of $23.33 and a 52 week high of $35.83. The firm’s 50 day moving average price is $31.02 and its 200-day moving average price is $30.26. The company has a market capitalization of $3.11 billion, a P/E ratio of -21.49 and a beta of 1.57.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a negative net margin of 5.76% and a positive return on equity of 6.60%. The business had revenue of $556.06 million during the quarter, compared to analysts’ expectations of $541.87 million. On average, analysts forecast that Evolent Health, Inc. will post 0.87 earnings per share for the current fiscal year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.